biostudies-literatureUnknown138(3)Angelucci SEisai Co. Ltd.We aimed to quantify inter- and intra-patient variability in serum perampanel concentrations and assess whether concentrations predict efficacy or tolerability. We conducted a retrospective cohort study of 68 children and adolescents (< 18 years) treated at the Danish Epilepsy Centre (2017-2024), analysing 311 TDM samples. Dose-normalized concentration ratio was summarized as the concentration-to-dose-per-kilogram ratio (C:(D/kg)) and evaluated by age group and co-medication category: enzyme-inducing anti-seizure medications (ASMs), valproate or non-inducing ASMs. Clinical outcomes were change in seizure burden, seizure freedom and adverse effects. Perampanel concentrations were outside the recommended therapeutic range in 13.8% of samples, and C:(D/kg) varied 59.2-fold across patients. ChBasic & clinical pharmacology & toxicologye70209https://www.ebi.ac.uk/biostudies/studies/S-EPMC12926690biostudies-literaturePharmacokinetics of Perampanel in Danish Paediatric Patients With Epilepsy Based on Therapeutic Drug Monitoring.PMC12926690Hansen AFHAngelucci SHansen MSHoulind MBShorter JRBayat AfalsePharmacokinetics of Perampanel in Danish Paediatric Patients With Epilepsy Based on Therapeutic Drug Monitoring.We aimed to quantify inter- and intra-patient variability in serum perampanel concentrations and assess whether concentrations predict efficacy or tolerability. We conducted a retrospective cohort study of 68 children and adolescents (< 18 years) treated at the Danish Epilepsy Centre (2017-2024), analysing 311 TDM samples. Dose-normalized concentration ratio was summarized as the concentration-to-dose-per-kilogram ratio (C:(D/kg)) and evaluated by age group and co-medication category: enzyme-inducing anti-seizure medications (ASMs), valproate or non-inducing ASMs. Clinical outcomes were change in seizure burden, seizure freedom and adverse effects. Perampanel concentrations were outside the recommended therapeutic range in 13.8% of samples, and C:(D/kg) varied 59.2-fold across patients. Ch2026-01-01T00:00:00Z2026 Mar2026-07-16T18:31:37.863Z2026-07-11T03:08:43.436ZS-EPMC129266904165600210.1111/bcpt.70209